Achieve Life Sciences (ACHV) Common Equity (2010 - 2026)

Achieve Life Sciences (ACHV) has 17 years of Common Equity data on file, last reported at $10.7 million in Q1 2026.

• Quarterly Common Equity rose 3.88% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (up 3.88% YoY) and the FY2025 annual result came in at $21.5 million, up 2.96% from the prior year.
• Common Equity declined to $10.7 million in Q1 2026, from $21.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $49.5 million in Q1 2024 to a low of -$1.4 million in Q4 2023.
• A 5-year average of $18.7 million and a median of $13.2 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity slumped 117.44% — and 2024, when it soared 11063.88%.
• Tracing ACHV's Common Equity over 5 years: stood at $8.3 million in 2022, then tumbled by 117.44% to -$1.4 million in 2023, then surged by 1543.3% to $20.9 million in 2024, then grew by 2.96% to $21.5 million in 2025, then tumbled by 50.38% to $10.7 million in 2026.
• The last three Common Equity figures came in at $10.7 million (Q1 2026), $21.5 million (Q4 2025), and $33.6 million (Q3 2025), per Business Quant data.